US5173414A
(en)
*
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US5252479A
(en)
*
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
US6261834B1
(en)
|
1991-11-08 |
2001-07-17 |
Research Corporation Technologies, Inc. |
Vector for gene therapy
|
US6268213B1
(en)
|
1992-06-03 |
2001-07-31 |
Richard Jude Samulski |
Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
|
US6340674B1
(en)
|
1993-03-26 |
2002-01-22 |
Thomas Jefferson University |
Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
|
US6686200B1
(en)
*
|
1993-08-31 |
2004-02-03 |
Uab Research Foundation |
Methods and compositions for the large scale production of recombinant adeno-associated virus
|
US6652850B1
(en)
|
1993-09-13 |
2003-11-25 |
Aventis Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
ES2220923T3
(es)
*
|
1993-11-09 |
2004-12-16 |
Medical College Of Ohio |
Lineas celulares estables capaces de expresar el gen de replicacion del virus adeno-asociado.
|
DE69433592T2
(de)
*
|
1993-11-09 |
2005-02-10 |
Targeted Genetics Corp., Seattle |
Die erzielung hoher titer des rekombinanten aav-vektors
|
FR2716682B1
(fr)
*
|
1994-01-28 |
1996-04-26 |
Centre Nat Rech Scient |
Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
|
FR2716893B1
(fr)
*
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
WO1995028493A1
(en)
*
|
1994-04-13 |
1995-10-26 |
The Rockefeller University |
Aav-mediated delivery of dna to cells of the nervous system
|
CA2158977A1
(en)
|
1994-05-09 |
1995-11-10 |
James G. Respess |
Retroviral vectors having a reduced recombination rate
|
US6013517A
(en)
*
|
1994-05-09 |
2000-01-11 |
Chiron Corporation |
Crossless retroviral vectors
|
US6814962B1
(en)
*
|
1994-06-02 |
2004-11-09 |
Aventis Pharma S.A. |
Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
|
US6204059B1
(en)
*
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
US5714170A
(en)
|
1994-11-16 |
1998-02-03 |
Thomas Jefferson University |
Method of inducing resistance to tumor growth
|
US6342390B1
(en)
|
1994-11-23 |
2002-01-29 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
|
US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
CA2207927A1
(en)
*
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant aav vectors
|
US5843742A
(en)
*
|
1994-12-16 |
1998-12-01 |
Avigen Incorporated |
Adeno-associated derived vector systems for gene delivery and integration into target cells
|
US5780296A
(en)
*
|
1995-01-17 |
1998-07-14 |
Thomas Jefferson University |
Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
|
FR2732357B1
(fr)
*
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
US5830725A
(en)
*
|
1995-04-28 |
1998-11-03 |
The Board Of Trustees For The Leland Stanford Junior University |
Rapid, stable high-titre production of recombing retrovirus
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
AU6043396A
(en)
*
|
1995-06-05 |
1996-12-24 |
University Of Alabama At Birmingham Research Foundation, The |
Composition and methods for creating syngeneic recombinant v irus-producing cells
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
US6040183A
(en)
*
|
1995-06-07 |
2000-03-21 |
University Of North Carloina At Chapel Hill |
Helper virus-free AAV production
|
AU707862B2
(en)
*
|
1995-06-07 |
1999-07-22 |
University Of North Carolina At Chapel Hill, The |
Helper virus-free aav production
|
US6093570A
(en)
*
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
US6187757B1
(en)
*
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
FR2737501B1
(fr)
|
1995-07-31 |
1997-10-24 |
Transgene Sa |
Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
|
US6027931A
(en)
*
|
1995-08-03 |
2000-02-22 |
Avigen, Inc. |
High-efficiency AA V helper functions
|
US6001650A
(en)
*
|
1995-08-03 |
1999-12-14 |
Avigen, Inc. |
High-efficiency wild-type-free AAV helper functions
|
US5622856A
(en)
*
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
US5801030A
(en)
*
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
WO1997016539A1
(fr)
*
|
1995-11-01 |
1997-05-09 |
Dnavec Research Inc. |
Virus sendai recombinant
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
EP0861267A4
(de)
*
|
1995-11-14 |
2000-02-02 |
Univ Jefferson |
Induktion und resistenz gegen tumorwachstum mittels loeslichem igf-1
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
US5874304A
(en)
*
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
GB9614699D0
(en)
*
|
1996-07-12 |
1996-09-04 |
John P Robarts Research Inst T |
Hybrid herpes virus-based vector for gene delivery and expression
|
CA2263796A1
(en)
*
|
1996-08-16 |
1998-02-26 |
Medical Research Council |
Self-replicating episomal expression vectors conferring tissue-specific gene expression
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
EP0933997A4
(de)
*
|
1996-09-06 |
2000-08-16 |
Chiron Corp |
Verfahren und zusammensetzungen für die leberspezifische verabreichung von therapeutischen molekülen unter verwendung rekombinanter aav vektoren
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
AU741605B2
(en)
|
1996-12-18 |
2001-12-06 |
Targeted Genetics Corporation |
AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
WO1998046778A1
(en)
|
1997-04-11 |
1998-10-22 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Transgenomic viruses and the use thereof
|
WO1998048005A1
(en)
|
1997-04-24 |
1998-10-29 |
University Of Washington |
Targeted gene modification by parvoviral vectors
|
BR9808697A
(pt)
|
1997-04-28 |
2000-07-11 |
Rhone Poulenc Rorer Sa |
Processo para inibir o crescimento de um tumor, vetor de adenovìrus defeituoso, vetor de vìrus, uso do mesmo, e, composição farmacêutica
|
US6541036B1
(en)
|
1997-05-29 |
2003-04-01 |
Thomas Jefferson University |
Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
|
US20040161409A1
(en)
*
|
1997-07-25 |
2004-08-19 |
Kurtzman Gary J. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
US6710036B2
(en)
|
1997-07-25 |
2004-03-23 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
US6221646B1
(en)
*
|
1997-07-31 |
2001-04-24 |
Chiron Corporation |
Materials and methods for simplified AAV production
|
US6037177A
(en)
*
|
1997-08-08 |
2000-03-14 |
Cell Genesys, Inc. |
Method for increasing the efficiency of recombinant AAV production
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US20030125278A1
(en)
*
|
1997-08-13 |
2003-07-03 |
Tang De-Chu C. |
Immunization of animals by topical applications of a salmonella-based vector
|
US6348450B1
(en)
*
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US20030045492A1
(en)
*
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
DK1944362T3
(en)
|
1997-09-05 |
2016-01-25 |
Genzyme Corp |
Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6989264B2
(en)
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
GB9721909D0
(en)
*
|
1997-10-17 |
1997-12-17 |
Cantab Pharma Res |
Gene delivery vectors and their uses
|
CA2308008A1
(en)
*
|
1997-10-21 |
1999-04-29 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus (aav) packaging cassettes for the production of recombinant aav vectors
|
US6642051B1
(en)
*
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
EP0915165B1
(de)
*
|
1997-11-05 |
2003-02-19 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Verfahren zur helfervirusfreien Verpackung einer Genvektor-DNA
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
PT1049767E
(pt)
|
1998-01-08 |
2005-10-31 |
Agronomique Inst Nat Rech |
Coelho transgenico que expressa uma lipoproteina (a) humana funcional
|
WO1999036544A2
(en)
|
1998-01-14 |
1999-07-22 |
Chiron S.P.A. |
Neisseria meningitidis antigens
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
ATE344322T1
(de)
|
1998-02-13 |
2006-11-15 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
CA2324225A1
(en)
*
|
1998-03-20 |
1999-09-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
WO2001031019A2
(en)
|
1999-10-29 |
2001-05-03 |
Chiron Spa |
Neisserial antigenic peptides
|
JP5102414B2
(ja)
|
1998-05-01 |
2012-12-19 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
髄膜炎菌抗原および組成物
|
ES2251831T3
(es)
*
|
1998-05-06 |
2006-05-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Inhibidores de la activacion de nf-kb.
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6436392B1
(en)
*
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
GB9811172D0
(en)
*
|
1998-05-22 |
1998-07-22 |
Royal Free Hosp School Med |
Virus production
|
ES2324540T3
(es)
*
|
1998-05-27 |
2009-08-10 |
Genzyme Corporation |
Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.
|
WO1999061643A1
(en)
*
|
1998-05-27 |
1999-12-02 |
University Of Florida |
Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
|
DE19833476B4
(de)
*
|
1998-07-24 |
2005-08-25 |
Huss, Ralf, Dr. |
Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
|
IL141403A0
(en)
*
|
1998-08-28 |
2002-03-10 |
Univ Duke |
Deleted adenoviruses and methods of making and administering the same
|
EP2942393A1
(de)
|
1998-09-04 |
2015-11-11 |
Genzyme Corporation |
Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
|
US6783972B1
(en)
|
1998-09-22 |
2004-08-31 |
University Of Florida Research Foundation |
Methods for large-scale production of recombinant AAV vectors
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
WO2000022152A1
(en)
*
|
1998-10-13 |
2000-04-20 |
Avigen, Inc. |
Compositions and methods for producing recombinant adeno-associated virus
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US7129043B1
(en)
|
1998-10-22 |
2006-10-31 |
Duke University |
Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
ES2340230T3
(es)
*
|
1998-11-10 |
2010-05-31 |
University Of North Carolina At Chapel Hill |
Vectores viricos y sus procedimientos de preparacion y administracion.
|
US6303362B1
(en)
*
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US6503717B2
(en)
|
1999-12-06 |
2003-01-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
CA2359747A1
(en)
*
|
1999-02-09 |
2000-08-17 |
Lexicon Genetics Incorporated |
Human uncoupling proteins and polynucleotides encoding the same
|
DE19905501B4
(de)
*
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US20040043488A1
(en)
*
|
1999-02-17 |
2004-03-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Adeno-associated viral gene-transfer vector system
|
US6258595B1
(en)
*
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
CN100392082C
(zh)
|
1999-04-30 |
2008-06-04 |
启龙股份公司 |
保守的奈瑟球菌抗原
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
EP1939300A1
(de)
|
1999-05-28 |
2008-07-02 |
Targeted Genetics Corporation |
Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
|
DK1180159T3
(da)
*
|
1999-05-28 |
2008-11-17 |
Targeted Genetics Corp |
Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
|
WO2000075365A2
(en)
*
|
1999-06-08 |
2000-12-14 |
University Of Iowa Research Foundation |
Compounds and methods to enhance raav transduction
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
US6545127B1
(en)
*
|
1999-06-28 |
2003-04-08 |
Oklahoma Medical Research Foundation |
Catalytically active recombinant memapsin and methods of use thereof
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
ES2308989T3
(es)
*
|
1999-08-09 |
2008-12-16 |
Targeted Genetics Corporation |
Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
|
EP1916258B1
(de)
|
1999-08-09 |
2014-04-23 |
Targeted Genetics Corporation |
Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren
|
US6410236B1
(en)
|
1999-09-01 |
2002-06-25 |
The Regents Of The University Of Michigan |
Correcting diastolic dysfunction in heart failure
|
US6627617B1
(en)
|
1999-10-01 |
2003-09-30 |
University Of North Carolina At Chapel Hill |
Temperature-sensitive regulation of viral vector production
|
JP2003511037A
(ja)
*
|
1999-10-01 |
2003-03-25 |
ジェノボ, インコーポレイテッド |
AAVrep/cap遺伝子を含むアデノウイルスを使用する組換えAAVの産生
|
US7115391B1
(en)
*
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
AU784420B2
(en)
*
|
1999-10-07 |
2006-03-30 |
University Of Iowa Research Foundation, The |
Adeno-associated viruses and uses thereof
|
WO2001025465A1
(en)
*
|
1999-10-07 |
2001-04-12 |
University Of Iowa Research Foundation |
Adeno-associated viruses and uses thereof
|
US7241447B1
(en)
*
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
EP1222269A1
(de)
|
1999-10-12 |
2002-07-17 |
Lexicon Genetics Incorporated |
Menschliche ldl rezeptorfamilieproteine und polynukleinesäuren die dafür kodieren
|
GB9924981D0
(en)
*
|
1999-10-21 |
1999-12-22 |
Univ Manchester |
Gene therapy
|
CA2426669A1
(en)
*
|
1999-10-22 |
2001-05-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
.alpha.1-3 galactosyltransferase gene and promoter
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
CN1416352B
(zh)
|
2000-01-17 |
2011-05-25 |
启龙股份公司 |
含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
|
WO2001059450A2
(en)
|
2000-02-08 |
2001-08-16 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger protein for drug discovery
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1287125B1
(de)
*
|
2000-04-28 |
2009-07-29 |
Asklepios Biopharmaceutical, Inc. |
Für das dystrophin-minigen kodierende dna-sequenzen und verfahren zu deren verwendung
|
US6790667B1
(en)
*
|
2000-05-30 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human mitochondrial proteins and polynucleotides encoding the same
|
EP1294391B1
(de)
*
|
2000-06-09 |
2012-08-15 |
Bristol-Myers Squibb Company |
Wirkstoffkombination zur verhinderung der transplantatabstossung
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
KR100545945B1
(ko)
*
|
2000-07-03 |
2006-01-25 |
갈라 디자인, 인크. |
발현 벡터
|
US20030224415A1
(en)
*
|
2001-06-29 |
2003-12-04 |
Gala Design, Inc. |
Selection free growth of host cells containing multiple integrating vectors
|
SI1935427T1
(en)
|
2000-07-03 |
2018-05-31 |
Bristol-Myers Squibb Company |
USE OF HEATED CTLA4 MUTANT MOLECULES
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
AU2001271614B2
(en)
*
|
2000-07-03 |
2007-05-31 |
Catalent Pharma Solutions, Llc |
Host cells containing multiple integrating vectors
|
AU2001278981A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Tom F Lue |
Prevention and treatment of sexual arousal disorders
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
EP1328543B1
(de)
|
2000-10-27 |
2009-08-12 |
Novartis Vaccines and Diagnostics S.r.l. |
Nukleinsäuren und proteine von gruppen a und b-streptokokken
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
EP1355918B9
(de)
|
2000-12-28 |
2012-01-25 |
Wyeth LLC |
Rekombinantes schutzprotein aus streptococcus pneumoniae
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
DE60239317D1
(de)
|
2001-01-12 |
2011-04-14 |
Novartis Vaccines & Diagnostic |
Nukleinsäure mukosale immunisierung
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
EP2228389B1
(de)
|
2001-04-13 |
2015-07-08 |
Human Genome Sciences, Inc. |
Antikörper gegen vaskulären Endothelwachstumsfaktor 2
|
US20020182595A1
(en)
*
|
2001-04-27 |
2002-12-05 |
Weitzman Matthew D. |
Method of identifying cellular regulators of adeno-associated virus (AAV)
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6946126B2
(en)
*
|
2001-06-04 |
2005-09-20 |
Duke University |
Replicating adenovirus vectors
|
WO2003000280A2
(en)
*
|
2001-06-22 |
2003-01-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Abin-mediated hepatitis protection
|
US7449562B2
(en)
*
|
2001-06-29 |
2008-11-11 |
Novartis Ag |
PERV screening method and use thereof
|
EP2280074A3
(de)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
US7211659B2
(en)
|
2001-07-05 |
2007-05-01 |
Chiron Corporation |
Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
|
US20030103939A1
(en)
*
|
2001-07-13 |
2003-06-05 |
Engelhardt John F. |
Pseudotyped adeno-associated viruses and uses thereof
|
US8241622B2
(en)
*
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
DE10137283A1
(de)
*
|
2001-08-01 |
2003-02-27 |
Deutsches Krebsforsch |
AAV-Vektor-Verpackungsplasmide zur Helfervirus-freien Herstellung pseudotypisierter AAV-Partikel über Einzeltransfektion
|
US6838285B2
(en)
|
2001-09-18 |
2005-01-04 |
Becton Dickinson |
Site specific recombinase based method for producing adenoviral vectors
|
CA2461290C
(en)
*
|
2001-09-24 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
EP1469730A4
(de)
*
|
2001-10-30 |
2006-02-01 |
|
Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
WO2003042361A2
(en)
*
|
2001-11-09 |
2003-05-22 |
Government Of The United States Of America, Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
NZ578982A
(en)
*
|
2001-11-13 |
2011-03-31 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby
|
US7544669B2
(en)
|
2001-11-21 |
2009-06-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Polynucleotide therapy
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
CA2472927A1
(en)
*
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
CA2369985A1
(en)
*
|
2002-01-18 |
2003-07-18 |
Duke University |
Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
|
AU2003202297C1
(en)
|
2002-01-25 |
2006-05-18 |
G2 Therapies Ltd |
Anti-C5aR antibodies and uses thereof
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
AU2003225791A1
(en)
*
|
2002-03-15 |
2003-09-29 |
Department Of Veterans Affairs, Rehabilitation R And D Service |
Methods and compositions for directing cells to target organs
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US20040038304A1
(en)
*
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
WO2003086451A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Centocor, Inc. |
Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
|
JP2005536231A
(ja)
*
|
2002-05-08 |
2005-12-02 |
イントロン,インコーポレーテッド |
アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
KR101086533B1
(ko)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
|
NZ562736A
(en)
*
|
2002-08-21 |
2009-07-31 |
Revivicor Inc |
Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
WO2004022716A2
(en)
*
|
2002-09-09 |
2004-03-18 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
DE60332377D1
(de)
|
2002-10-21 |
2010-06-10 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
DE60333032D1
(de)
*
|
2002-10-23 |
2010-07-29 |
Virxsys Corp |
Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
|
EP2322186A3
(de)
|
2002-11-21 |
2011-07-13 |
Bayhill Therapeutics, Inc. |
Verfahren und immunmodulierende Nukleinsäurekomponenten zur Vorbeugung und Behandlung von Krankheiten
|
AU2002953436A0
(en)
*
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
WO2004056853A2
(en)
*
|
2002-12-23 |
2004-07-08 |
Vib Vzw |
An immunomodulatory protein derived from trypanosomes and uses thereof
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
MXPA05007615A
(es)
*
|
2003-01-21 |
2005-09-30 |
Bristol Myers Squibb Co |
Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
|
JP5433133B2
(ja)
|
2003-01-22 |
2014-03-05 |
デューク・ユニヴァーシティ |
リソソームポリペプチドを発現するための改善された構築物
|
JP2007524379A
(ja)
*
|
2003-03-31 |
2007-08-30 |
ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン |
上皮ナトリウムチャンネル関連障害のPharmico−遺伝子治療
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20070073048A1
(en)
|
2003-05-15 |
2007-03-29 |
Ying Lian |
Hiv polynucleotides and polypeptides derived from botswana mj4
|
ATE490307T1
(de)
|
2003-05-21 |
2010-12-15 |
Genzyme Corp |
Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
|
US20050036988A1
(en)
*
|
2003-05-28 |
2005-02-17 |
Ruian Xu |
Compositions and methods for preventing and treating liver cirrhosis
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
CA2534296C
(en)
|
2003-08-08 |
2013-03-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20070134796A1
(en)
*
|
2005-07-26 |
2007-06-14 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
ATE518960T1
(de)
|
2003-09-19 |
2011-08-15 |
Sangamo Biosciences Inc |
Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
|
EP1685148A2
(de)
*
|
2003-11-05 |
2006-08-02 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Porcines isoglobosid-3-synthaseprotein, cdna, genomische organisation und regulatorische region
|
US20050221429A1
(en)
*
|
2004-01-16 |
2005-10-06 |
Cardinal Health Pts, Llc |
Host cells containing multiple integrating vectors comprising an amplifiable marker
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
CA2553828A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
|
WO2005070948A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
WO2005089411A2
(en)
|
2004-03-17 |
2005-09-29 |
Revivicor, Inc. |
Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
|
JP4792390B2
(ja)
|
2004-03-29 |
2011-10-12 |
株式会社ガルファーマ |
新規ガレクチン9改変体タンパク質及びその用途
|
US20050223202A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Intel Corporation |
Branch prediction in a pipelined processor
|
EP1732945B1
(de)
*
|
2004-04-08 |
2014-12-24 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur modulation der kardialen kontraktivität
|
ATE418346T1
(de)
*
|
2004-04-08 |
2009-01-15 |
Sangamo Biosciences Inc |
Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20080131962A1
(en)
|
2006-05-25 |
2008-06-05 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
WO2006020684A2
(en)
|
2004-08-10 |
2006-02-23 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
EP1786473A4
(de)
*
|
2004-08-11 |
2008-11-19 |
Cedars Sinai Medical Center |
Behandlung von parkinson-krankheit und verwandter erkrankungen
|
EP2338524B1
(de)
|
2004-08-12 |
2013-05-22 |
Cedars-Sinai Medical Center |
Kombinierte Gentherapie zur Behandlung makroskopischer Glioma
|
US20060063231A1
(en)
*
|
2004-09-16 |
2006-03-23 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
EP2305294B1
(de)
|
2004-09-22 |
2015-04-01 |
GlaxoSmithKline Biologicals SA |
Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
CN101506355B
(zh)
|
2004-09-24 |
2012-06-27 |
成血管细胞系统公司 |
多能扩增间充质前体细胞子代(memp)及其应用
|
EP2361970A1
(de)
|
2004-09-24 |
2011-08-31 |
Angioblast Systems Incorporated |
Verfahren zur Verbesserung der Vermehrung und/oder des Überlebens von Mesenchymalvorläuferzellen (MPC)
|
MX2007003850A
(es)
|
2004-10-05 |
2007-11-21 |
Genzyme Corp |
Canula escalonada.
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
AU2005326784B2
(en)
*
|
2004-10-08 |
2012-03-15 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
NZ555830A
(en)
*
|
2004-12-15 |
2009-01-31 |
Univ North Carolina |
Chimeric vectors
|
US7524510B2
(en)
*
|
2005-02-23 |
2009-04-28 |
The Uab Research Foundation |
Alkyl-glycoside enhanced vaccination
|
US7358085B2
(en)
*
|
2005-02-28 |
2008-04-15 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
CN107033243B
(zh)
|
2005-03-23 |
2020-12-15 |
根马布股份公司 |
用于治疗多发性骨髓瘤的cd38抗体
|
EP1869165B1
(de)
*
|
2005-04-12 |
2015-10-21 |
Mesoblast, Inc. |
Isolierung adulter multipotenzieller zellen mittels gewebeunspezifischer alkalischer phosphatase
|
CA2604909A1
(en)
*
|
2005-04-15 |
2006-10-26 |
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services |
Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
|
EP2816118B1
(de)
|
2005-05-31 |
2018-10-17 |
The Regents of the University of Colorado, a body corporate |
Verfahren zur Bereitstellung von Genen
|
US20060275812A1
(en)
*
|
2005-06-01 |
2006-12-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Assay for agonists and antagonists of ion channels and for regulators of genetic expression
|
WO2006132925A2
(en)
*
|
2005-06-01 |
2006-12-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
AU2006279896A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating Alzheimer's disease
|
US7858590B2
(en)
*
|
2005-08-11 |
2010-12-28 |
Cedars-Sinai Medical Center |
Treatment of parkinson's disease and related disorders
|
PT3272872T
(pt)
|
2005-10-20 |
2020-06-26 |
Uniqure Ip Bv |
Vetores aav melhorados produzidos em células de insetos
|
EP2360175B1
(de)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus und sapovirus virusähnliche partikel (vlps)
|
US20070134204A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Henrich Cheng |
Method for treating nerve injury and vector construct for the same
|
EP1962883B1
(de)
|
2005-12-22 |
2012-10-10 |
VIB, vzw |
Mittel und verfahren zur vermittlung von protein-interferenz
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
AU2007239095B2
(en)
|
2006-01-09 |
2012-05-03 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
ES2388443T3
(es)
|
2006-03-29 |
2012-10-15 |
Dana-Farber Cancer Institute, Inc. |
Métodos y composiciones para inducir una respuesta inmune frente a VIH y modelos para ensayo
|
CA2651180A1
(en)
*
|
2006-04-28 |
2007-11-08 |
University Of Iowa Research Foundation |
Methods and compounds to alter virus infection
|
CA2650414A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivation of dihydrofolate reductase
|
US20110206692A1
(en)
|
2006-06-09 |
2011-08-25 |
Novartis Ag |
Conformers of bacterial adhesins
|
CN103849629B
(zh)
|
2006-06-21 |
2017-06-09 |
尤尼克尔Ip股份有限公司 |
具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
US20100035973A1
(en)
*
|
2006-07-17 |
2010-02-11 |
Nationwide Children's Hospital, Inc. |
Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
|
MY151438A
(en)
|
2006-07-28 |
2014-05-30 |
Sanofi Aventis |
Compositions and method for treatment of tumors
|
CA2660156A1
(en)
*
|
2006-08-22 |
2008-02-28 |
G2 Inflammation Pty Ltd |
Anti-c5ar antibodies with improved properties
|
ES2385679T3
(es)
|
2006-08-24 |
2012-07-30 |
Virovek, Inc. |
Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
|
CN101588816B
(zh)
|
2006-10-19 |
2013-06-19 |
Csl有限公司 |
白介素-13受体α1的高亲和性抗体拮抗物
|
PL2068922T3
(pl)
|
2006-10-19 |
2012-11-30 |
Csl Ltd |
Przeciwciała anty-IL-13R alfa1 i ich zastosowania
|
US8685720B2
(en)
*
|
2006-11-03 |
2014-04-01 |
The Trustees Of Princeton University |
Engineered cellular pathways for programmed autoregulation of differentiation
|
US20080113915A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Duke University |
SAPAP3 knockout mouse and clinical modeling associated with the SAPAP3 gene
|
CA2693178C
(en)
*
|
2006-11-29 |
2018-12-04 |
Nationwide Children's Hospital, Inc. |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US8883493B2
(en)
*
|
2007-01-30 |
2014-11-11 |
Cedars-Sinai Medical Center |
Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
|
CN101678082B
(zh)
|
2007-03-26 |
2013-06-19 |
再生医药有限公司 |
使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
|
CN101680002B
(zh)
*
|
2007-04-23 |
2011-11-23 |
核力康健生物医药技术(天津)有限公司 |
一组重组腺相关病毒载体及其构建方法与应用
|
US8258286B2
(en)
|
2007-04-26 |
2012-09-04 |
University Of Iowa Research Foundation |
Reduction of off-target RNA interference toxicity
|
US20090036395A1
(en)
|
2007-04-26 |
2009-02-05 |
Davidson Beverly L |
Rna interference suppression of neurodegenerative diseases and methods of use thereof
|
KR101510778B1
(ko)
|
2007-07-12 |
2015-04-10 |
상가모 바이오사이언스 인코포레이티드 |
알파 1,6 당전이효소(fut8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물
|
ES2923016T3
(es)
|
2007-08-06 |
2022-09-22 |
Mesoblast Inc |
Células precursoras mesenquimales TNAP+ para el tratamiento de enfermedades del tejido conectivo
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
KR101383476B1
(ko)
|
2007-11-01 |
2014-04-11 |
아스테라스 세이야쿠 가부시키가이샤 |
면역억제 폴리펩티드 및 핵산
|
KR20100117120A
(ko)
|
2008-02-20 |
2010-11-02 |
지투 인플레메이션 피티와이 엘티디 |
인간화된 항-C5aR 항체
|
US8597912B2
(en)
|
2008-06-10 |
2013-12-03 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of Bax-and Bak-deficient cell lines
|
CN105030828B
(zh)
|
2008-06-25 |
2020-10-02 |
麦瑟布莱斯特公司 |
椎间盘的修复和/或重建
|
EP3121597A1
(de)
|
2008-08-18 |
2017-01-25 |
Mesoblast, Inc. |
Monoklonaler antikörper stro-4
|
KR20160015400A
(ko)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
CN102203122A
(zh)
|
2008-11-05 |
2011-09-28 |
惠氏有限责任公司 |
用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
|
EP2350266B1
(de)
|
2008-11-20 |
2015-07-29 |
Mesoblast, Inc. |
Verfahren zur behandlung oder verhinderung einer pankreas-dysfunktion
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
AU2010203223B9
(en)
|
2009-01-05 |
2015-10-08 |
Epitogenesis Inc. |
Adjuvant compositions and methods of use
|
BRPI1007155A2
(pt)
|
2009-01-29 |
2017-05-30 |
Univ Of California San Francisco |
métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata
|
AU2010211057B2
(en)
|
2009-02-04 |
2014-12-18 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathies
|
EP2396343B1
(de)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
|
EP3293257B1
(de)
|
2009-03-20 |
2021-08-11 |
Mesoblast, Inc. |
Herstellung von umprogrammierten pluripotenten zellen
|
CN102448501A
(zh)
|
2009-03-27 |
2012-05-09 |
西马生物医学计划公司 |
治疗肝硬化和肝纤维化的方法和组合物
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
CA2759801C
(en)
|
2009-05-02 |
2019-04-02 |
Marco A. Passini |
Gene therapy for neurodegenerative disorders
|
CA2797480A1
(en)
|
2009-06-15 |
2010-12-23 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides
|
EP2451475A2
(de)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Selbstreplizierende rna-moleküle und ihre verwendung
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
AU2010281705B2
(en)
|
2009-07-28 |
2015-02-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
WO2011066048A1
(en)
|
2009-10-22 |
2011-06-03 |
Thomas Jefferson University |
Cell-based anti-cancer compositions and methods of making and using the same
|
BR112012010755A2
(pt)
|
2009-11-05 |
2015-09-22 |
Proyecto Biomedicina Cima Sl |
constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
JP2013518602A
(ja)
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
EP3502254A1
(de)
|
2010-04-23 |
2019-06-26 |
Cold Spring Harbor Laboratory |
Neuartige strukturell designte shrnas
|
EP3156062A1
(de)
|
2010-05-17 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Neuartige dna-bindende proteine und verwendungen davon
|
CA2803641A1
(en)
|
2010-07-02 |
2012-01-05 |
Mesoblast, Inc. |
Treatment of t-cell mediated immune disorders
|
WO2012015938A2
(en)
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
SI3246044T2
(sl)
|
2010-08-23 |
2024-06-28 |
Wyeth Llc |
Stabilne formulacije antigenov neisseria meningitidis RLP2086
|
ES2585328T5
(es)
|
2010-09-10 |
2022-12-14 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
TR201903651T4
(tr)
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
EP2627359B1
(de)
|
2010-10-15 |
2015-12-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Expressionsvektor für 24-hydrolase zur behandlungder huntington-krankheit
|
CA2816971A1
(en)
|
2010-11-05 |
2012-05-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Light-activated chimeric opsins and methods of using the same
|
ES2625179T3
(es)
|
2010-11-05 |
2017-07-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Control optogenético de comportamientos relacionados con la recompensa
|
JP2013544600A
(ja)
|
2010-11-23 |
2013-12-19 |
プレサージュ バイオサイエンシズ,インコーポレイテッド |
固体デリバリーのための治療方法および組成物
|
TR201908715T4
(tr)
|
2011-01-26 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Rsv immünizasyon rejimi.
|
WO2012109667A1
(en)
|
2011-02-12 |
2012-08-16 |
University Of Iowa Research Foundation |
Therapeutic compounds
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
WO2012145509A2
(en)
|
2011-04-19 |
2012-10-26 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors, and viruses
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
EP2699673B1
(de)
|
2011-04-21 |
2018-09-19 |
Nationwide Children's Hospital, Inc. |
Rekombinante virusprodukte und verfahren zur expressionshemmung von myotilin
|
PL2707385T3
(pl)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Prefuzyjne antygeny RSV F
|
CN103826646A
(zh)
|
2011-06-03 |
2014-05-28 |
麦瑟布莱斯特公司 |
治疗中风的影响的方法
|
ES2693647T3
(es)
|
2011-06-06 |
2018-12-13 |
Novo Nordisk A/S |
Anticuerpos terapéuticos
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
AU2012273153A1
(en)
|
2011-06-21 |
2013-05-02 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
JP6499446B2
(ja)
|
2011-06-24 |
2019-04-10 |
エピットジェネシス・インコーポレーテッド |
抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
|
EP3653218A1
(de)
|
2011-07-04 |
2020-05-20 |
Mesoblast, Inc. |
Verfahren zur behandlung oder prävention rheumatischer erkrankungen
|
EP3461896B1
(de)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Verfahren zur transkription einer aktivatorähnlichen effektoranordnung
|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
EP3290055B1
(de)
|
2011-07-25 |
2024-08-28 |
Nationwide Children's Hospital, Inc. |
Rekombinante virusprodukte und verfahren zur expressionshemmung von dux4
|
WO2013032918A1
(en)
|
2011-08-26 |
2013-03-07 |
Yecuris Corporation |
Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
|
TR201809635T4
(tr)
|
2011-09-09 |
2018-07-23 |
Mesoblast Inc |
Osteoblastik fonksiyonun arttırılmasına yönelik yöntemler.
|
CN103917644A
(zh)
|
2011-09-21 |
2014-07-09 |
桑格摩生物科学股份有限公司 |
调控转基因表达的方法和组合物
|
MX2014004214A
(es)
|
2011-10-11 |
2014-05-07 |
Novartis Ag |
Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
|
EP2766385A2
(de)
|
2011-10-12 |
2014-08-20 |
Novartis AG |
Cmv-antigene und verwendungen davon
|
AU2012321102C1
(en)
|
2011-10-27 |
2016-11-10 |
Pharma Cinq, Llc |
Vectors encoding rod-derived cone viability factor
|
EP2771455B1
(de)
*
|
2011-10-28 |
2016-10-05 |
The University of North Carolina At Chapel Hill |
Zelllinie zur produktion eines adenoassoziierten virus
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
AU2012352429B2
(en)
|
2011-12-16 |
2018-07-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opsin polypeptides and methods of use thereof
|
ES2728077T3
(es)
|
2012-02-21 |
2019-10-22 |
Univ Leland Stanford Junior |
Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico
|
AU2013225950B2
(en)
|
2012-02-29 |
2018-02-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating huntington's disease
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
RU2665841C2
(ru)
|
2012-03-09 |
2018-09-04 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их применения
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
KR20150021088A
(ko)
|
2012-06-05 |
2015-02-27 |
디 오스트레일리언 내셔널 유니버시티 |
인터루킨-4 길항제를 이용한 백신접종
|
EP3818991A3
(de)
|
2012-06-19 |
2021-07-14 |
University of Florida Research Foundation, Inc. |
Zusammensetzungen und verfahren zur behandlung von krankheiten
|
JP6329537B2
(ja)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
生物学的薬剤の送達のための方法および組成物
|
EP3196301B1
(de)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von monogener krankheiten
|
DK2879719T3
(en)
|
2012-08-01 |
2018-09-03 |
Nationwide Childrens Hospital |
INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
|
CA2880811C
(en)
|
2012-08-01 |
2021-12-07 |
United Therapeutics Corporation |
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
|
WO2014022373A1
(en)
|
2012-08-01 |
2014-02-06 |
United Therapeutics Corporation |
Treatment of pulmonary arterial hypertension with mesenchymal stem cells
|
DK2890780T3
(da)
|
2012-08-29 |
2020-09-21 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
|
JP2015529685A
(ja)
|
2012-09-17 |
2015-10-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute Atnationwide Children’S Hospital |
筋萎縮性側索硬化症の処置のための組成物および方法
|
EP3763810A3
(de)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T-zell-modifizierende verbindungen und verwendungen davon
|
US20150267176A1
(en)
|
2012-10-12 |
2015-09-24 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
CN105142529A
(zh)
|
2012-11-21 |
2015-12-09 |
电路治疗公司 |
用于光遗传疗法的系统和方法
|
BR112015013311A2
(pt)
|
2012-12-07 |
2017-11-14 |
Haplomics Inc |
indução de tolerancia e reparação de mutação do fator 8
|
SG11201504523UA
(en)
|
2012-12-12 |
2015-07-30 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
EP2931899A1
(de)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
EP3031921A1
(de)
|
2012-12-12 |
2016-06-15 |
The Broad Institute, Inc. |
Ausgabe, bearbeitung und optimierung von systeme, verfahren und zusammensetzungen für sequenzmanipulation und therapeutische anwendungen
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
KR20150105633A
(ko)
|
2012-12-12 |
2015-09-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 시스템, 방법 및 최적화된 가이드 조성물의 조작
|
DK3064585T3
(da)
|
2012-12-12 |
2020-04-27 |
Broad Inst Inc |
Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
|
EP4286402A3
(de)
|
2012-12-12 |
2024-02-14 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen mit crispr-cas-komponenten zur sequenzmanipulation
|
SG10201705061RA
(en)
|
2012-12-12 |
2017-07-28 |
Mesoblast Inc |
Treatment of Diseases of Endothelial Dysfunction and Inflammation
|
CA2897444A1
(en)
|
2013-01-08 |
2014-07-17 |
Genzyme Corporation |
Use of inos inhibitors to increase viral yield in culture
|
EP3878452B1
(de)
|
2013-01-09 |
2023-09-20 |
United Therapeutics Corporation |
Behandlung von vaskulopathie mit prostacyclin und mesenchymalen stammzellen
|
US9066966B2
(en)
|
2013-02-01 |
2015-06-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
AU2014218854B2
(en)
|
2013-02-20 |
2019-01-24 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of Pompe disease
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
US20140296139A1
(en)
|
2013-03-15 |
2014-10-02 |
The Regents Of The University Of California |
Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
JP6594854B2
(ja)
|
2013-03-15 |
2019-10-23 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
行動状態の光遺伝学的制御方法
|
US9644215B2
(en)
|
2013-04-12 |
2017-05-09 |
The General Hospital Corporation |
AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
|
SG10201708547YA
(en)
|
2013-04-17 |
2017-11-29 |
Genzyme Corp |
Compositions and methods for treating and preventing macular degeneration
|
CA2909807C
(en)
|
2013-04-20 |
2023-08-08 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
|
JP6549559B2
(ja)
|
2013-04-29 |
2019-07-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
KR20160056869A
(ko)
|
2013-06-17 |
2016-05-20 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
CA2915845A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
EP4245853A3
(de)
|
2013-06-17 |
2023-10-18 |
The Broad Institute, Inc. |
Optimierte crispr-cas-doppel-nickase-systeme, verfahren und zusammensetzungen zur sequenzmanipulation
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
CA2915842C
(en)
|
2013-06-17 |
2022-11-29 |
The Broad Institute, Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
CN106062197A
(zh)
|
2013-06-17 |
2016-10-26 |
布罗德研究所有限公司 |
用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
EP3033427A4
(de)
|
2013-08-14 |
2017-05-31 |
The Board Of Trustees Of The University Of the Leland Stanford Junior University |
Zusammensetzungen und verfahren zur bekämpfung von schmerzen
|
ES2799437T3
(es)
|
2013-08-27 |
2020-12-17 |
The Res Institute At Nationwide Childrens Hospital |
Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica
|
EP3988654A1
(de)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
WO2015031686A1
(en)
|
2013-08-30 |
2015-03-05 |
Amgen Inc. |
High titer recombinant aav vector production in adherent and suspension cells
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
EP3041502A2
(de)
|
2013-09-08 |
2016-07-13 |
Pfizer Inc. |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
ES2881473T3
(es)
|
2013-10-17 |
2021-11-29 |
Sangamo Therapeutics Inc |
Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas
|
JP2016537995A
(ja)
|
2013-11-05 |
2016-12-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
新しいアルツハイマー病動物モデル
|
EP3065784A4
(de)
|
2013-11-05 |
2017-05-10 |
The Research Institute at Nationwide Children's Hospital |
Zusammensetzungen und verfahren zur hemmung von nf-kb und sod-1 zur behandlung von amyotropher lateralsklerose
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
PL3492593T3
(pl)
|
2013-11-13 |
2022-04-19 |
Children's Medical Center Corporation |
Regulacja ekspresji genów, w której pośredniczą nukleazy
|
WO2015073707A1
(en)
|
2013-11-15 |
2015-05-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
EP3757116A1
(de)
|
2013-12-09 |
2020-12-30 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für genom-engineering
|
AU2014361784A1
(en)
|
2013-12-12 |
2016-06-23 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
|
WO2015089462A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
CN106536729A
(zh)
|
2013-12-12 |
2017-03-22 |
布罗德研究所有限公司 |
使用粒子递送组分靶向障碍和疾病的crispr‑cas系统和组合物的递送、用途和治疗应用
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
WO2015117081A2
(en)
|
2014-02-03 |
2015-08-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
MX2016010215A
(es)
|
2014-02-06 |
2016-11-15 |
Genzyme Corp |
Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
|
EP3107939B1
(de)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Abgabe einer nrf2-therapie zum schutz gegen reaktive sauerstoffspezies
|
WO2015124546A1
(en)
|
2014-02-19 |
2015-08-27 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic |
Aav vectors for the treatment of ischemic and non-ischemic heart disease
|
CA2942762C
(en)
|
2014-03-18 |
2023-10-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
AU2015231231B2
(en)
|
2014-03-21 |
2021-09-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
EP3122761B1
(de)
|
2014-03-28 |
2019-03-06 |
The Board of Trustees of The Leland Stanford Junior University |
Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
CN107075514A
(zh)
|
2014-05-20 |
2017-08-18 |
衣阿华大学研究基金会 |
亨廷顿氏病的治疗化合物
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
AU2015277369B2
(en)
|
2014-06-16 |
2021-08-19 |
The Johns Hopkins University |
Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
EP3180426B1
(de)
|
2014-08-17 |
2019-12-25 |
The Broad Institute, Inc. |
Gemonbearbeitung mit cas9-nickasen
|
RS62334B1
(sr)
|
2014-09-16 |
2021-10-29 |
Sangamo Therapeutics Inc |
Postupci i sastavi za inženjering genoma posredovan nukleazom i korekciju kod matičnih ćelija hematopoeze
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
US10842886B2
(en)
|
2014-10-10 |
2020-11-24 |
Research Institute At Nationwide Children's Hospital |
Guided injections for AAV gene transfer to muscle
|
EP3690024A1
(de)
|
2014-11-05 |
2020-08-05 |
The Research Institute at Nationwide Children's Hospital |
Verfahren und materialien zur herstellung rekombinanter viren in eukaryotischen mikroalgen
|
MX2017005834A
(es)
|
2014-11-05 |
2017-11-17 |
Voyager Therapeutics Inc |
Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
|
RU2749882C2
(ru)
|
2014-11-14 |
2021-06-18 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
EP3218484A4
(de)
|
2014-11-14 |
2018-05-30 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
EP3230452A1
(de)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Totführungen für crispr-transkriptionsfaktoren
|
KR102526616B1
(ko)
|
2014-12-17 |
2023-04-27 |
푼다시온 파라 라 인베스티가시온 메디카 아플리카다 |
윌슨병 및 기타 병태의 치료에 사용되기 위한 핵산 구조물 및 유전자 치료용 벡터
|
WO2016097218A1
(en)
|
2014-12-17 |
2016-06-23 |
Fundación Para La Investigación Mèdica Aplicada |
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
EP3054006A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
|
EP3054007A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
|
RU2723045C2
(ru)
|
2015-02-19 |
2020-06-08 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их получения
|
EP3262171A2
(de)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
JP2018511655A
(ja)
|
2015-03-20 |
2018-04-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
|
EP3273999A1
(de)
|
2015-03-23 |
2018-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur behandlung und prävention von neurologischem phänotyp im zusammenhang mit friedreich-ataxie
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
アデノ随伴ウイルス変異体及びその使用方法
|
CA2981077A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
US11795435B2
(en)
|
2015-05-05 |
2023-10-24 |
Mesoblast International Sárl; |
Potency assay
|
EP4276106A3
(de)
|
2015-05-13 |
2024-01-24 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
US20180161395A1
(en)
|
2015-06-12 |
2018-06-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical composition for the treatment of alzheimer's disease
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2017004022A2
(en)
|
2015-06-29 |
2017-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Degron fusion constructs and methods for controlling protein production
|
ES2895652T3
(es)
|
2015-07-07 |
2022-02-22 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
|
EP3322297A4
(de)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
AU2016323575B2
(en)
|
2015-09-17 |
2022-10-27 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for GALGT2 gene therapy
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
WO2017070605A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
IL294014B2
(en)
|
2015-10-23 |
2024-07-01 |
Harvard College |
Nucleobase editors and their uses
|
CA3000931A1
(en)
|
2015-10-28 |
2017-05-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of duchenne muscular dystrophy
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
MX2018005332A
(es)
|
2015-11-06 |
2018-11-09 |
Crispr Therapeutics Ag |
Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
|
CA3005633C
(en)
|
2015-11-16 |
2023-11-21 |
Research Institute Of Nationwide Children's Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopathies
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
EP3384024B1
(de)
|
2015-12-01 |
2022-02-02 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
|
EP3384034B1
(de)
|
2015-12-02 |
2020-07-08 |
The Board of Trustees of the Leland Stanford Junior University |
Neue rekombinante kapside des adeno-associated virus mit erhöhtem tropismus für menschliche skelett- muskulatur
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
EP3389677B1
(de)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Gezielte zerstörung des t-zell-rezeptors
|
JP2018537112A
(ja)
|
2015-12-18 |
2018-12-20 |
サンガモ セラピューティクス, インコーポレイテッド |
Mhc細胞受容体の標的化破壊
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
MX2018007840A
(es)
|
2015-12-23 |
2019-05-02 |
Crispr Therapeutics Ag |
Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
|
WO2017120589A1
(en)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
JP6930052B2
(ja)
|
2016-01-15 |
2021-09-01 |
サンガモ セラピューティクス, インコーポレイテッド |
神経性疾患の処置のための方法および組成物
|
JP7219452B2
(ja)
|
2016-01-19 |
2023-02-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
遺伝子治療ベクターおよび医薬組成物
|
EP3411056A4
(de)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
EP3411078A1
(de)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
EP3417055B1
(de)
|
2016-02-16 |
2021-10-13 |
The Board of Trustees of the Leland Stanford Junior University |
Gegen vorhandene humane neuartige antikörper resistente, neuartige rekombinante adeno-assoziierte virus-kapside
|
US20190112353A1
(en)
|
2016-02-18 |
2019-04-18 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
CA3015633A1
(en)
|
2016-02-26 |
2017-08-31 |
Research Institute At Nationwide Children's Hospital |
Recombinant virus products and methods for inducing dux4 exon skipping
|
AU2017229347A1
(en)
|
2016-03-07 |
2018-11-01 |
University Of Iowa Research Foundation |
AAV-mediated expression using a synthetic promoter and enhancer
|
EP3429632B1
(de)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von erblicher haemochromatose
|
HUE061100T2
(hu)
|
2016-03-28 |
2023-05-28 |
Ultragenyx Pharmaceutical Inc |
Adenovírus hõinaktiválásának módszerei
|
BR112018070256A2
(pt)
|
2016-03-31 |
2019-01-29 |
Spark Therapeutics Inc |
processo de fabricação de raav totalmente escalável à base de colunas
|
BR112018070249A2
(pt)
|
2016-04-02 |
2019-01-29 |
Research Institute At Nationwide Children's Hospital |
sistema promotor de u6 modificada para expressão específica de tecido
|
LT3442600T
(lt)
|
2016-04-15 |
2024-05-27 |
Research Institute At Nationwide Children's Hospital |
Su adeno virusu susijusio viruso vektoriaus iš β-sarkoglikano ir mikro- rnr-29 pristatymas ir raumenų distrofijos gydymas
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
US20200330609A1
(en)
|
2016-04-18 |
2020-10-22 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2017184768A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2017184786A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Cpf1 complexes with reduced indel activity
|
EP3448874A4
(de)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
RU2758488C2
(ru)
|
2016-05-18 |
2021-10-28 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
JP7220080B2
(ja)
|
2016-05-18 |
2023-02-09 |
ボイジャー セラピューティクス インコーポレイテッド |
ハンチントン病治療組成物及び方法
|
JP2020511931A
(ja)
|
2016-06-16 |
2020-04-23 |
オスロ ウニヴェルスィテーツスィーケフース ハーエフOslo Universitetssykehus Hf |
改良された遺伝子編集
|
WO2017219027A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute Inc. |
Type vi crispr orthologs and systems
|
EP3478828B1
(de)
|
2016-06-29 |
2024-09-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
EP3478829A1
(de)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materialien und verfahren zur behandlung von myotoner dystrophie typ 1 (dm1) und anderen erkrankungen
|
CA3029860A1
(en)
|
2016-07-05 |
2018-01-11 |
The Johns Hopkins University |
Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
|
CN109843914B
(zh)
|
2016-07-06 |
2024-03-15 |
沃泰克斯药物股份有限公司 |
用于治疗疼痛相关病症的材料和方法
|
AU2017292169B2
(en)
|
2016-07-06 |
2021-12-23 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
EP4321623A3
(de)
|
2016-07-15 |
2024-05-15 |
Salk Institute for Biological Studies |
Verfahren und zusammensetzungen zum genom-editieren von sich nichtteilenden zellen
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
IL308426A
(en)
|
2016-08-03 |
2024-01-01 |
Harvard College |
Adenosine nuclear base editors and their uses
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
BR112019002394B1
(pt)
|
2016-08-10 |
2021-12-21 |
Ajou University Industry-Academic Cooperation Foundation |
Proteína heterodimérica fundida com fc e seu uso
|
CN110114461A
(zh)
|
2016-08-17 |
2019-08-09 |
博德研究所 |
新型crispr酶和系统
|
EP3500670B1
(de)
|
2016-08-17 |
2024-07-10 |
The Broad Institute, Inc. |
Verfahren um zielsequenzen für guide rna von crispr systemen auszuwählen
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
KR20220145913A
(ko)
|
2016-08-24 |
2022-10-31 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
PE20190568A1
(es)
|
2016-08-24 |
2019-04-22 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas
|
EP3506817A4
(de)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
|
EP3526321A4
(de)
|
2016-10-14 |
2020-05-13 |
Ultragenyx Pharmaceutical Inc. |
Verwendung von tonifizierenden mitteln zur verbesserung der ausbeute von rekombinantem adeno-assoziiertem virus
|
SG11201903089RA
(en)
|
2016-10-14 |
2019-05-30 |
Harvard College |
Aav delivery of nucleobase editors
|
US11219695B2
(en)
|
2016-10-20 |
2022-01-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
ES2927406T3
(es)
|
2016-10-24 |
2022-11-04 |
United Therapeutics Corp |
Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
CA3042853A1
(en)
|
2016-11-07 |
2018-05-11 |
Crossbeta Biosciences B.V. |
Novel amyloid beta oligomer specific binding molecule
|
AU2017362491B2
(en)
|
2016-11-17 |
2023-02-02 |
Nationwide Children's Hospital Inc. |
Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
|
WO2018106782A1
(en)
|
2016-12-08 |
2018-06-14 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
CN110191955B
(zh)
|
2016-12-13 |
2024-05-31 |
西雅图儿童医院(Dba西雅图儿童研究所) |
在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
WO2018138360A1
(en)
|
2017-01-28 |
2018-08-02 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
Oxygen carrying blood substitutes and their use as delivery vehicles
|
US20190343927A1
(en)
|
2017-01-30 |
2019-11-14 |
Brainvectis |
Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
|
IL267733B2
(en)
|
2017-01-31 |
2023-10-01 |
Pfizer |
NEISSERIA MENINGITIDIS preparations and methods therefor
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
EP3585900B1
(de)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materialien und methoden zur behandlung von spinocerebellar ataxia typ 2 (sca2) und anderen spinocerebellar ataxia typ 2 protein (atxn2) gen verwandten erkrankungen oder störungen
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
EP3585899A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
EP3592777A1
(de)
|
2017-03-10 |
2020-01-15 |
President and Fellows of Harvard College |
Cytosin-zu-guanin-baseneditor
|
JP2020513811A
(ja)
|
2017-03-17 |
2020-05-21 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
JP7142643B2
(ja)
|
2017-03-22 |
2022-09-27 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
Hdac阻害剤またはrepタンパク質を伴う細胞培養方法
|
JP7191388B2
(ja)
|
2017-03-23 |
2022-12-19 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸によってプログラム可能なdna結合蛋白質を含む核酸塩基編集因子
|
WO2018172527A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of neurodegenerative disease
|
WO2018195555A1
(en)
|
2017-04-21 |
2018-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
|
EP3615674B1
(de)
|
2017-04-28 |
2024-03-13 |
The Regents of the University of Colorado, A Body Corporate |
Verfahren zur behandlung von rheumatoider arthritis mit rna-geführter genombearbeitung des hla-gens
|
EP3619294A1
(de)
|
2017-05-04 |
2020-03-11 |
Mesoblast International Sàrl |
Mesenchymale linienvorläufer oder stammzellen mit erhöhter immunsuppression
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
WO2018204786A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
US11872262B2
(en)
|
2017-05-09 |
2024-01-16 |
Vib Vzw |
Means and methods for treating bacterial infections
|
US20210278416A1
(en)
|
2017-05-09 |
2021-09-09 |
The Broad Institute, Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
IL270415B2
(en)
|
2017-05-12 |
2024-08-01 |
Crispr Therapeutics Ag |
Materials and methods for cell engineering and their uses in immuno-oncology
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
EP3642334B1
(de)
|
2017-06-23 |
2023-12-27 |
Inscripta, Inc. |
Nukleinsäure-geführte nukleasen
|
CA3064601A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
US20200370069A1
(en)
|
2017-07-08 |
2020-11-26 |
Genethon |
Treatment of spinal muscular atrophy
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
EP3662060A2
(de)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
WO2019053272A1
(en)
|
2017-09-15 |
2019-03-21 |
King's College London |
COMPOSITIONS AND METHODS FOR IMPROVING T GAMMA DELTA LYMPHOCYTES IN INTESTINE
|
EP3684397A4
(de)
|
2017-09-21 |
2021-08-18 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen zur gezielten nukleinsäureeditierung
|
US20200231986A1
(en)
|
2017-09-29 |
2020-07-23 |
Massachusetts Eye And Ear Infirmary |
Production of adeno-associated viruses in insect cells
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
EP4124658A3
(de)
|
2017-10-16 |
2023-04-19 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
EP3697908A1
(de)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
CA3079172A1
(en)
|
2017-10-17 |
2019-04-25 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
US11534501B2
(en)
|
2017-10-18 |
2022-12-27 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
CA3079416A1
(en)
|
2017-10-20 |
2019-04-25 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for nt-3 gene therapy
|
MA50849A
(fr)
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
CA3081436A1
(en)
|
2017-10-31 |
2019-05-09 |
Western Oncolytics Ltd. |
Platform oncolytic vector for systemic delivery
|
IL314692A
(en)
|
2017-11-08 |
2024-10-01 |
Novartis Ag |
Means and method for preparing viral vectors and their uses
|
EP3707155A2
(de)
|
2017-11-09 |
2020-09-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas-systeme für die behandlung von dmd
|
EP3714055A1
(de)
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
|
JP2021503968A
(ja)
|
2017-11-28 |
2021-02-15 |
ミリムス インコーポレイテッド |
RNAiモデルの遺伝的工学的手法
|
AU2018386301A1
(en)
|
2017-12-14 |
2020-06-18 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and their use in genome editing and other applications
|
EP3728595A1
(de)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
|
WO2019123429A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
CN111741955B
(zh)
|
2018-01-17 |
2024-02-23 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
CA3088791A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
MA51619A
(fr)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
Inhibiteurs de la protéine kinase dépendante de l'adn
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
EP3749768A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
WO2019160383A1
(ko)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
|
EP3755795A4
(de)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-assoziierte viruszusammensetzungen zur wiederherstellung der f8-genfunktion und verfahren zur verwendung davon
|
WO2019178428A1
(en)
|
2018-03-14 |
2019-09-19 |
Arbor Biotechnologies, Inc. |
Novel crispr dna and rna targeting enzymes and systems
|
DE202019005567U1
(de)
|
2018-03-14 |
2021-02-16 |
Arbor Biotechnologies, Inc. |
Neue CRISPR-DNA-Targeting-Enzyme und -Systeme
|
US20210070819A1
(en)
|
2018-03-16 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
WO2019175381A1
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
CA3092497A1
(en)
|
2018-03-19 |
2019-09-26 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and uses thereof
|
JP7378417B2
(ja)
|
2018-03-30 |
2023-11-13 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
増強されたヒト膵臓トロピズムを有する新規な組換えアデノ随伴ウイルスキャプシド
|
US12037707B2
(en)
|
2018-04-05 |
2024-07-16 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation
|
IT201800004253A1
(it)
|
2018-04-05 |
2019-10-05 |
|
Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
JP2021521852A
(ja)
|
2018-04-27 |
2021-08-30 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
Aadcウイルスベクターの効力を測定する方法
|
KR20210016353A
(ko)
|
2018-04-27 |
2021-02-15 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
라파마이신 내성 세포
|
AU2019266327A1
(en)
|
2018-05-11 |
2020-11-26 |
Beam Therapeutics Inc. |
Methods of editing single nucleotide polymorphism using programmable base editor systems
|
EP3794127A1
(de)
|
2018-05-14 |
2021-03-24 |
Vivet Therapeutics |
Gentherapeutische vektoren mit s/mar-sequenzen
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
MA52631A
(fr)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics Inc |
Compositions et méthodes pour le traitement de la maladie de parkinson
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
US20210198330A1
(en)
|
2018-05-23 |
2021-07-01 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
CA3102840A1
(en)
|
2018-06-05 |
2019-12-12 |
Lifeedit, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
JP7478675B2
(ja)
|
2018-06-08 |
2024-05-07 |
ノバルティス アーゲー |
薬物製品の効力を測定するための細胞ベースアッセイ
|
GB201809588D0
(en)
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
SG11202012450QA
(en)
|
2018-06-18 |
2021-01-28 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
CA3104471A1
(en)
|
2018-06-18 |
2019-12-26 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
|
US20210277362A1
(en)
|
2018-06-29 |
2021-09-09 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
JP7565218B2
(ja)
|
2018-07-02 |
2024-10-10 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
KR20210030965A
(ko)
|
2018-07-12 |
2021-03-18 |
로켓 파마슈티컬스, 리미티드 |
다논병을 치료하기 위한 유전자 요법 벡터
|
WO2020018142A1
(en)
|
2018-07-16 |
2020-01-23 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
EP3833761A1
(de)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Neuartige cas12b-enzyme und systeme
|
US20210317429A1
(en)
|
2018-08-20 |
2021-10-14 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
CN110857440B
(zh)
|
2018-08-23 |
2021-02-19 |
武汉纽福斯生物科技有限公司 |
重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
|
EP3844284A1
(de)
|
2018-08-29 |
2021-07-07 |
Research Institute at Nationwide Children's Hospital |
Produkte und verfahren zur hemmung der expression von mutierten gars-proteinen
|
EP3853244A4
(de)
|
2018-09-18 |
2022-09-14 |
Sangamo Therapeutics, Inc. |
Für programmierten zelltod 1 (pd1) spezifische nukleasen
|
WO2020069461A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
JP2022512621A
(ja)
|
2018-10-05 |
2022-02-07 |
ボイジャー セラピューティクス インコーポレイテッド |
Aav産生タンパク質をコードする操作された核酸コンストラクト
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
JP2022508724A
(ja)
|
2018-10-12 |
2022-01-19 |
ヴィヴェ テラピューティクス |
進行性家族性肝内胆汁鬱滞タイプ3(pfic3)の治療のためのコドン最適化導入遺伝子
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
EP3867375A1
(de)
|
2018-10-15 |
2021-08-25 |
Fondazione Telethon |
Genomeditierungsverfahren und konstrukte
|
WO2020081843A1
(en)
|
2018-10-17 |
2020-04-23 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for delivering transgenes
|
MA53919A
(fr)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics Inc |
Constructions d'acides nucléiques et procédés d'utilisation
|
SG11202104136YA
(en)
|
2018-10-23 |
2021-05-28 |
Dragonfly Therapeutics Inc |
Heterodimeric fc-fused proteins
|
HUE060949T2
(hu)
|
2018-10-29 |
2023-04-28 |
Inst Nat Sante Rech Med |
Koleszterin 24-hidroláz expressziós vektor amiotrófiás laterálszklerózis kezelésében
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
CN111118016B
(zh)
|
2018-10-30 |
2022-04-15 |
上海朗昇生物科技有限公司 |
治疗视网膜色素变性疾病的基因治疗载体
|
SG11202104634UA
(en)
|
2018-11-07 |
2021-06-29 |
Vivet Therapeutics |
Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2)
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
AU2019389047A1
(en)
|
2018-11-30 |
2021-05-20 |
Novartis Ag |
AAV viral vectors and uses thereof
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
US20220042045A1
(en)
|
2018-12-21 |
2022-02-10 |
Genethon |
Expression cassettes for gene therapy vectors
|
IL312708A
(en)
|
2018-12-27 |
2024-07-01 |
Lifeedit Therapeutics Inc |
Polypeptides useful for gene editing and methods of use
|
KR20210110345A
(ko)
|
2018-12-31 |
2021-09-07 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
RNA 표적화 CRISPR-Cas13b를 사용한 DUX4 RNA 침묵화
|
CN113631173A
(zh)
|
2019-01-02 |
2021-11-09 |
迈索布拉斯特国际有限公司 |
治疗腰痛的方法
|
KR20210110822A
(ko)
|
2019-01-03 |
2021-09-09 |
메조블라스트 인터내셔널 에스에이알엘 |
시력 향상을 위한 방법
|
US20220064671A1
(en)
|
2019-01-18 |
2022-03-03 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
JP2022519597A
(ja)
|
2019-02-04 |
2022-03-24 |
リサーチ・インスティチュート・アット・ネーションワイド・チルドレンズ・ホスピタル |
Cln6ポリヌクレオチドのアデノ随伴ウイルス送達
|
BR112021015285A2
(pt)
|
2019-02-04 |
2021-10-05 |
Research Institute At Nationwide Children's Hospital |
Entrega de vírus adenoassociado de polinucleotídeo cln3
|
SG11202108357PA
(en)
|
2019-02-15 |
2021-08-30 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
WO2020172624A1
(en)
|
2019-02-22 |
2020-08-27 |
Life Technologies Corporation |
Suspension system for adeno associated virus production
|
US20230241252A1
(en)
|
2019-02-26 |
2023-08-03 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
US20220170013A1
(en)
|
2019-03-06 |
2022-06-02 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020186059A2
(en)
|
2019-03-12 |
2020-09-17 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
US20220177863A1
(en)
|
2019-03-18 |
2022-06-09 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
CN111718418B
(zh)
|
2019-03-19 |
2021-08-27 |
华东师范大学 |
一种增强基因编辑的融合蛋白及其应用
|
WO2020191243A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
US20220154153A1
(en)
|
2019-03-22 |
2022-05-19 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
EP4335925A3
(de)
|
2019-04-09 |
2024-08-28 |
The Regents of the University of California |
Langanhaltende analgesie durch gezielte epigenetische in-vivo-repression
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
BR112021020391A2
(pt)
|
2019-04-12 |
2022-02-08 |
Ultragenyx Pharmaceutical Inc |
Linhagens de células produtoras projetadas e métodos para preparar e usar as mesmas
|
CA3137080A1
(en)
|
2019-04-15 |
2020-10-22 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
EP3962536A1
(de)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systeme und verfahren zur herstellung von baculovirusinfizierten insektenzellen (biics) in bioreaktoren
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
EP3736330A1
(de)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Partikel mit modifiziertem adeno-assoziiertem virus (aav) zur gentherapie
|
US20210047649A1
(en)
|
2019-05-08 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
AR118696A1
(es)
|
2019-05-17 |
2021-10-27 |
Res Institute At Nationwide ChildrenS Hospital |
Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2020234363A2
(en)
|
2019-05-21 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
|
WO2020234450A1
(en)
|
2019-05-23 |
2020-11-26 |
Mesoblast International Sarl |
Functional recovery from cerebral infarction
|
WO2020243485A1
(en)
|
2019-05-29 |
2020-12-03 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
EP3990636A1
(de)
|
2019-06-28 |
2022-05-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur steuerung der geneditierung
|
CA3145446A1
(en)
|
2019-07-02 |
2021-01-07 |
Fundacion Para La Investigacion Medica Aplicada |
Cpla2e inducing agents and uses thereof
|
CN112180094A
(zh)
|
2019-07-04 |
2021-01-05 |
上海东慈生物科技有限公司 |
Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
JP2022542839A
(ja)
|
2019-07-19 |
2022-10-07 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
リコンビナーゼ組成物及び使用方法
|
KR20220035937A
(ko)
|
2019-07-25 |
2022-03-22 |
노파르티스 아게 |
조절 가능한 발현 시스템
|
US20220315906A1
(en)
|
2019-08-08 |
2022-10-06 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
EP4010465A1
(de)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
US20220364074A1
(en)
|
2019-08-12 |
2022-11-17 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
WO2021032069A1
(en)
|
2019-08-16 |
2021-02-25 |
Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences |
Treatment of neuronal diseases
|
HUE066215T2
(hu)
|
2019-08-21 |
2024-07-28 |
Res Institute At Nationwide |
Alfa-szarkoglikán bevitele adenoasszociáltvírus-vektorral és izomdisztrófia kezelése
|
US20220364114A1
(en)
|
2019-08-26 |
2022-11-17 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
EP4028522A1
(de)
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Zusammensetzungen und verfahren für sod1-targeting
|
AU2020345830A1
(en)
|
2019-09-09 |
2022-03-24 |
Beam Therapeutics Inc. |
Novel CRISPR enzymes, methods, systems and uses thereof
|
EP4028064A1
(de)
|
2019-09-12 |
2022-07-20 |
The Broad Institute, Inc. |
Manipulierte adeno-assoziierte viruskapside
|
WO2021072129A2
(en)
|
2019-10-08 |
2021-04-15 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
CA3158286A1
(en)
|
2019-10-18 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
US20220389453A1
(en)
|
2019-10-18 |
2022-12-08 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of disorders associated with the irf2bpl gene
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
JP2023502474A
(ja)
|
2019-11-22 |
2023-01-24 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Ighmbp2遺伝子に関連する障害の治療のための材料および方法
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
WO2021113763A1
(en)
|
2019-12-06 |
2021-06-10 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of rhodopsin
|
WO2021113769A1
(en)
|
2019-12-07 |
2021-06-10 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of htt
|
CA3165469A1
(en)
|
2019-12-20 |
2021-06-24 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy for targeting muscle in muscle diseases
|
JP2023508731A
(ja)
|
2019-12-30 |
2023-03-03 |
ライフエディット セラピューティクス,インコーポレイティド |
Rna誘導ヌクレアーゼ、その活性断片および多様体、ならびに使用方法
|
KR20220125332A
(ko)
|
2020-01-10 |
2022-09-14 |
스크라이브 테라퓨틱스 인크. |
Pcsk9의 표적화를 위한 조성물 및 방법
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
EP4097124A1
(de)
|
2020-01-28 |
2022-12-07 |
The Broad Institute Inc. |
Baseneditoren, zusammensetzungen und verfahren zur modifizierung des mitochondrialen genoms
|
EP4100519A2
(de)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adeninbaseneditoren und verwendungen davon
|
WO2021158999A1
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
CN115485382A
(zh)
|
2020-02-18 |
2022-12-16 |
全国儿童医院研究所 |
X连锁病症的治疗中的AAV介导的MiRNA靶向
|
US11642407B2
(en)
|
2020-02-28 |
2023-05-09 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
AU2021239973A1
(en)
|
2020-03-16 |
2022-10-06 |
Ultragenyx Pharmaceutical Inc. |
Methods for enhancing recombinant adeno-associated virus yield
|
WO2021188729A1
(en)
|
2020-03-18 |
2021-09-23 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of c9orf72
|
EP4121168A1
(de)
|
2020-03-20 |
2023-01-25 |
University of Florida Research Foundation, Inc. |
Gentherapie für das schabyne-syndrom
|
GB202004498D0
(en)
|
2020-03-27 |
2020-05-13 |
Ucl Business Ltd |
Activity-dependent gene therapy for neurological disorders
|
CA3173999A1
(en)
|
2020-03-30 |
2021-10-07 |
Wuhan Neurophth Biotechnology Limited Company |
Expression vector of human nuclear factor e2-related factor 2 and application of expression vector
|
CA3174863A1
(en)
|
2020-04-14 |
2021-10-21 |
Ana BUJ BELLO |
Vectors for the treatment of acid ceramidase deficiency
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
AU2021260960A1
(en)
|
2020-04-22 |
2022-11-24 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
US20230279440A1
(en)
|
2020-05-06 |
2023-09-07 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
CN115803435A
(zh)
|
2020-05-06 |
2023-03-14 |
塞勒克提斯公司 |
用于在细胞基因组中靶向插入外源序列的方法
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
WO2021231437A1
(en)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復pah基因功能的腺相關病毒組成物及其使用方法
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
WO2021250079A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
CA3185503A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Nrf2 activator for use in treating dilated cardiomyopathies
|
EP4162048A1
(de)
|
2020-06-09 |
2023-04-12 |
Genethon |
Behandlung von genetischen dilatierten kardiomyopathien
|
AU2021293197A1
(en)
|
2020-06-15 |
2023-02-09 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
CA3173949A1
(en)
|
2020-07-15 |
2022-01-20 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
CN117120619A
(zh)
|
2020-07-27 |
2023-11-24 |
沃雅戈治疗公司 |
用于治疗与葡萄糖神经酰胺酶β缺陷相关的神经病症的组合物和方法
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
TW202214864A
(zh)
|
2020-08-06 |
2022-04-16 |
應用醫學研究基金會 |
用於藉基因療法治療諸如阿茲海默症之Tau蛋白病變的病毒顆粒
|
KR20230043869A
(ko)
|
2020-08-07 |
2023-03-31 |
스페이스크래프트 세븐, 엘엘씨 |
Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
|
US20230265456A1
(en)
|
2020-08-10 |
2023-08-24 |
Fundacion Para La Investigacion Medica Aplicada |
Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
|
WO2022034374A2
(en)
|
2020-08-11 |
2022-02-17 |
University Of Oslo |
Improved gene editing
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
TW202227624A
(zh)
|
2020-09-11 |
2022-07-16 |
美商生命編輯治療學公司 |
Dna修飾酶及活性片段,及其變異體與使用方法
|
US20230357795A1
(en)
|
2020-09-15 |
2023-11-09 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
|
JP2023543029A
(ja)
|
2020-09-28 |
2023-10-12 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーの治療のための製品及び方法
|
CA3200563A1
(en)
|
2020-09-29 |
2022-04-07 |
Genethon |
Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof
|
US20220290136A1
(en)
|
2020-09-30 |
2022-09-15 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
MX2023003994A
(es)
|
2020-10-09 |
2023-04-24 |
UCB Biopharma SRL |
Construcciones de acido nucleico, vectores virales y particulas virales.
|
IL302046A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Nucleic acid structures for va RNA transcription
|
US20220154223A1
(en)
|
2020-10-15 |
2022-05-19 |
Hoffmann-La Roche Inc. |
Nucleic acid constructs for simultaneous gene activation
|
JP2023548067A
(ja)
|
2020-11-02 |
2023-11-15 |
バイオマリン ファーマシューティカル インコーポレイテッド |
アデノ随伴ウイルスを濃縮するためのプロセス
|
CN116648448A
(zh)
|
2020-11-11 |
2023-08-25 |
欧洲分子生物学实验室 |
用于基因治疗的修饰病毒粒子
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
WO2022115745A1
(en)
|
2020-11-30 |
2022-06-02 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
WO2022120089A1
(en)
|
2020-12-03 |
2022-06-09 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of ptbp1
|
US20220228142A1
(en)
|
2020-12-17 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
EP4267197A1
(de)
|
2020-12-23 |
2023-11-01 |
Vivet Therapeutics |
Durch minimale gallensäure induzierbare promotoren zur gentherapie
|
AU2022212922A1
(en)
|
2021-01-27 |
2023-08-17 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
US20240093191A1
(en)
|
2021-02-03 |
2024-03-21 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating disease associated with dux4 overexpression
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
JP2024508324A
(ja)
|
2021-03-04 |
2024-02-26 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dmdエクソンの重複を修正するためのcrispr-cas9を使用したジストロフィンベースのミオパチーの治療のための生成物及び方法
|
WO2022188797A1
(en)
|
2021-03-09 |
2022-09-15 |
Huigene Therapeutics Co., Ltd. |
Engineered crispr/cas13 system and uses thereof
|
TW202300649A
(zh)
|
2021-03-22 |
2023-01-01 |
美商生命編輯治療學公司 |
Dna修飾酶及活性片段及其變體及使用方法
|
KR20230158531A
(ko)
|
2021-03-23 |
2023-11-20 |
빔 테라퓨틱스, 인크. |
신규 crispr 효소, 방법, 시스템 및 그 용도
|
EP4323010A1
(de)
|
2021-04-13 |
2024-02-21 |
Research Institute at Nationwide Children's Hospital |
Rekombinantes adeno-assoziiertes virus, das für methyl-cpg-bindendes protein 2 codiert, zur behandlung des pitt-hopkins-syndroms durch intrathekale verabreichung
|
EP4323501A1
(de)
|
2021-04-16 |
2024-02-21 |
Beam Therapeutics Inc. |
Genetische modifikation von hepatozyten
|
CA3216491A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
AU2022262420A1
(en)
|
2021-04-23 |
2023-11-16 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
JP2024516400A
(ja)
|
2021-04-30 |
2024-04-15 |
カリヴィル イムノセラピューティクス, インコーポレイテッド |
修飾されたmhc発現のための腫瘍溶解性ウイルス
|
WO2022234295A1
(en)
|
2021-05-07 |
2022-11-10 |
Ucl Business Ltd |
Abca4 genome editing
|
KR20240021765A
(ko)
|
2021-05-17 |
2024-02-19 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근이영양증 치료를 위한 재조합 aav 벡터의 제조
|
WO2022243565A1
(en)
|
2021-05-21 |
2022-11-24 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
EP4349979A4
(de)
|
2021-05-27 |
2024-08-21 |
Inst Zoology Cas |
Manipulierte cas12i-nuklease, effektorprotein und verwendung davon
|
EP4108263A3
(de)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
|
EP4351592A1
(de)
|
2021-06-09 |
2024-04-17 |
Universität Duisburg-Essen |
Verfahren zur immortalisierung von vesikel-sekretierenden zellen
|
US20240287487A1
(en)
|
2021-06-11 |
2024-08-29 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
EP4352214A1
(de)
|
2021-06-11 |
2024-04-17 |
Bayer AG |
Typ-v-rna-programmierbare endonukleasesysteme
|
WO2022261394A1
(en)
|
2021-06-11 |
2022-12-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
WO2023004367A2
(en)
|
2021-07-20 |
2023-01-26 |
The Broad Institute, Inc. |
Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
JP2024530050A
(ja)
|
2021-08-11 |
2024-08-14 |
キングス・カレッジ・ロンドン |
中枢神経系に影響を及ぼす障害の改善された治療のための組成物及び方法
|
EP4384628A2
(de)
|
2021-08-11 |
2024-06-19 |
Solid Biosciences Inc. |
Behandlung von muskeldystrophie
|
WO2023023227A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
EP4396201A1
(de)
|
2021-09-03 |
2024-07-10 |
BioMarin Pharmaceutical Inc. |
Aav-kapsid-zusammensetzungen und verfahren zur freisetzung
|
JP2024533174A
(ja)
|
2021-09-03 |
2024-09-12 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
Aavカプシド組成物及び送達方法
|
WO2023034996A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
EP4396203A1
(de)
|
2021-09-03 |
2024-07-10 |
BioMarin Pharmaceutical Inc. |
Aav-kapsid-zusammensetzungen und verfahren zur freisetzung
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
JP2024533311A
(ja)
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
ゲノムを調節するための方法及び組成物
|
CN117980484A
(zh)
|
2021-09-16 |
2024-05-03 |
诺华股份有限公司 |
新颖的转录因子
|
EP4405396A2
(de)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von her2-positivem krebs
|
AU2022360382A1
(en)
|
2021-10-07 |
2024-05-09 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
WO2023060233A1
(en)
|
2021-10-08 |
2023-04-13 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
EP4219726A1
(de)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Selbstkomplementärer adeno-assoziierter virusvektor und dessen verwendung bei der behandlung von muskeldystrophie
|
EP4419684A1
(de)
|
2021-10-21 |
2024-08-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Retroelementerzeugte transkriptionsfaktorköder
|
KR20240099360A
(ko)
|
2021-10-28 |
2024-06-28 |
유씨비 바이오파마 에스알엘 |
핵산 구축물, 바이러스 벡터 및 바이러스 입자
|
WO2023077078A1
(en)
|
2021-10-29 |
2023-05-04 |
Ultragenyx Pharmaceutical Inc. |
Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
|
CA3237300A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674B
(zh)
|
2021-11-02 |
2024-08-30 |
辉大(上海)生物科技有限公司 |
一种CRISPR-Cas12i系统
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
EP4433490A2
(de)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen im zusammenhang mit glucosylceramidase-beta-mangel
|
EP4186919A1
(de)
|
2021-11-30 |
2023-05-31 |
Research Institute at Nationwide Children's Hospital |
Selbstkomplementärer adeno-assoziierter virusvektor und dessen verwendung bei der behandlung von muskeldystrophie
|
EP4198046A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
|
EP4198134A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
|
EP4198048A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
|
EP4198047A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
|
CA3240917A1
(en)
|
2021-12-17 |
2023-06-22 |
Bernd ZETSCHE |
Crispr enzymes, methzods, systems and uses thereof
|
WO2023122669A1
(en)
|
2021-12-21 |
2023-06-29 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
IL313765A
(en)
|
2021-12-22 |
2024-08-01 |
Tome Biosciences Inc |
Joint provision of a gene editor structure and a donor template
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023131682A1
(en)
|
2022-01-06 |
2023-07-13 |
Ucl Business Ltd |
Endogenous gene regulation to treat neurological disorders and diseases
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023147511A2
(en)
*
|
2022-01-28 |
2023-08-03 |
Shape Therapeutics Inc. |
Systems for amplification of aav rep and cap proteins
|
GB202201744D0
(en)
|
2022-02-10 |
2022-03-30 |
Ucl Business Ltd |
Treatment of acquired focal epilepsy
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
AU2023227586A1
(en)
|
2022-03-03 |
2024-09-12 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
AU2023248451A1
(en)
|
2022-04-04 |
2024-10-17 |
President And Fellows Of Harvard College |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220693A1
(en)
|
2022-05-12 |
2023-11-16 |
SunVax mRNA Therapeutics Inc. |
Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
|
WO2023222829A1
(en)
|
2022-05-17 |
2023-11-23 |
Centre Hospitalier Universitaire Vaudois |
Designed biosensors for enhanced t cell therapy
|
WO2023225564A1
(en)
|
2022-05-18 |
2023-11-23 |
The Broad Institute, Inc. |
Engineered viral capsids with increased stability and methods of use thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240157A2
(en)
|
2022-06-08 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of dmd
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024038168A1
(en)
|
2022-08-19 |
2024-02-22 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042165A2
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024042168A1
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|
WO2024056902A2
(en)
|
2022-09-16 |
2024-03-21 |
Christopher Shaw |
Compositions and methods for treating neurological diseases
|
WO2024064913A1
(en)
|
2022-09-23 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Recombinant aav vectors for treating muscular dystrophy
|
WO2024081706A1
(en)
|
2022-10-11 |
2024-04-18 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
|
WO2024092126A1
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for improved immunotherapies
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
WO2024095245A2
(en)
|
2022-11-04 |
2024-05-10 |
LifeEDIT Therapeutics, Inc. |
Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
|
WO2024129743A2
(en)
|
2022-12-13 |
2024-06-20 |
Bluerock Therapeutics Lp |
Engineered type v rna programmable endonucleases and their uses
|
WO2024126696A1
(en)
|
2022-12-14 |
2024-06-20 |
King's College London |
Compositions and methods for treating neurological diseases
|
WO2024127370A1
(en)
|
2022-12-16 |
2024-06-20 |
LifeEDIT Therapeutics, Inc. |
Guide rnas that target trac gene and methods of use
|
WO2024127369A1
(en)
|
2022-12-16 |
2024-06-20 |
LifeEDIT Therapeutics, Inc. |
Guide rnas that target foxp3 gene and methods of use
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
WO2024145474A2
(en)
|
2022-12-29 |
2024-07-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
WO2024147114A1
(en)
|
2023-01-06 |
2024-07-11 |
Bloomsbury Genetic Therapies Limited |
Compositions and methods for treating parkinson's disease
|
WO2024151982A1
(en)
|
2023-01-13 |
2024-07-18 |
Amicus Therapeutics, Inc. |
Gene therapy constructs for the treatment of pompe disease
|
WO2024163560A1
(en)
|
2023-02-01 |
2024-08-08 |
Sarepta Therapeutics, Inc. |
Raav production methods
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
WO2024161142A1
(en)
|
2023-02-02 |
2024-08-08 |
Quethera Limited |
Recombinant adeno-associated virus vector
|
WO2024161022A2
(en)
|
2023-02-03 |
2024-08-08 |
King's College London |
Compositions and methods for treating neurological diseases
|
WO2024163842A2
(en)
|
2023-02-03 |
2024-08-08 |
The Broad Institute, Inc. |
Delivering genes to the brain endothelium to treat lysosomal storage disorder-derived neuropathology
|
WO2024163862A2
(en)
|
2023-02-03 |
2024-08-08 |
The Broad Institute, Inc. |
Gene editing methods, systems, and compositions for treating spinal muscular atrophy
|
WO2024165456A1
(en)
|
2023-02-07 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Method for the detection of anti-aav particle antibodies
|
WO2024168276A2
(en)
|
2023-02-09 |
2024-08-15 |
Cargo Therapeutics, Inc. |
Compositions and methods for immunotherapies
|
WO2024194280A1
(en)
|
2023-03-21 |
2024-09-26 |
F. Hoffmann-La Roche Ag |
Method for the production of recombinant aav particle preparations
|
WO2024206928A1
(en)
|
2023-03-30 |
2024-10-03 |
Pharma Cinq, Llc |
VECTOR ENCODING ROD-DERIVED CONE VIABILITY FACTOR AND HUMAN IgK SIGNAL SEQUENCE
|
WO2024211394A1
(en)
|
2023-04-03 |
2024-10-10 |
Decibel Therapeutics, Inc. |
Modified rep-cap plasmids and uses thereof
|